SEARCH

SEARCH BY CITATION

References

  • 1
    Deshpande N, Addess KJ, Bluhm WF, Merino-Ott JC, Townsend-Merino W, Zhang Q, Knezevich C, Xie L, Chen L, Feng Z, Green RK, Flippen-Anderson JL, Westbrook J, Berman HM, Bourne PE ( 2005) The RCSB protein data bank: a redesigned query system and relational database based on the mmCIF schema. Nucleic Acids Res 33: D233D237.
  • 2
    Alvarez JC ( 2004) High-throughput docking as a source of novel drug leads. Curr Opin Chem Biol 8: 365370.
  • 3
    Bohacek RS, McMartin C, Guida WC ( 1996) The art and practice of structure-based drug design: a molecular modeling perspective. Med Res Rev 16: 350.
  • 4
    Hardy LW, Malikayil A ( 2003) The impact of structure-guided drug design on clinical agents. Curr Drug Discov December, 1520.
  • 5
    Hajduk PJ ( 2006) Fragment-based drug design: how big is too big? J Med Chem 49: 69726697.
  • 6
    Rawlings ND, Morton FR, Kok CY, Kong J, Barrett AJ ( 2008) MEROPS: the peptidase database. Nucleic Acids Res 36: D320D325.
  • 7
    Allcorn LC, Martin AC ( 2002) SACS–self-maintaining database of antibody crystal structure information. Bioinformatics 18: 175181.
  • 8
    Jacobs MD, Caron PR, Hare BJ ( 2008) Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex. Proteins 70: 14511460.
  • 9
    Hendlich M, Bergner A, Gunther J, Klebe G ( 2003) Relibase: design and development of a database for comprehensive analysis of protein-ligand interactions. J Mol Biol 326: 607620.
  • 10
    Bergner A, Gunther J, Hendlich M, Klebe G, Verdonk M ( 2001) Use of Relibase for retrieving complex three-dimensional interaction patterns including crystallographic packing effects. Biopolymers 61: 99110.
  • 11
    Schreyer A, Blundell T ( 2009) CREDO: a protein-ligand interaction database for drug discovery. Chem Biol Drug Des 73: 157167.
  • 12
    Hu L, Benson ML, Smith RD, Lerner MG, Carlson HA ( 2005) Binding MOAD (Mother of all databases). Proteins 60: 333340.
  • 13
    Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK ( 2007) BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 35: D198D201.
  • 14
    Chen X, Liu M, Gilson MK ( 2001) BindingDB: a web-accessible molecular recognition database. Comb Chem High Throughput Screen 4: 719725.
  • 15
    Brooijmans N, Mobilio D, Walker G, Nilakantan R, Denny RA, Feyfant E, Diller D, Bikker JA, Humblet C (in press) Structural informatics approaches to mine kinase knowledge-bases. Drug Discov Today doi:10.1016/j.drudis.2009.11.005.
  • 16
    Cohen P ( 2002) Protein kinases–the major drug targets of the twenty-first century? Nat Rev Drug Discov 1: 309315.
  • 17
    Bikker JA, Brooijmans N, Wissner A, Mansour TS ( 2009) Kinase domain mutations in cancer: implications for small molecule drug design strategies. J Med Chem 52: 14931509.
  • 18
    Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S ( 2002) The protein kinase complement of the human genome. Science 298: 19121934.
  • 19
    Zhang Y, Skolnick J ( 2005) TM-align: a protein structure alignment algorithm based on the TM-score. Nucleic Acids Res 33: 23022309.
  • 20
    Akamine P, Madhusudan J, Xuong NH, Ten Eyck LF, Taylor SS ( 2003) Dynamic features of cAMP-dependent protein kinase revealed by apoenzyme crystal structure. J Mol Biol 327: 159171.
  • 21
    Wu J, Yang J, Kannan N, Madhusudan NH, Ten Eyck LF, Taylor SS ( 2005) Crystal structure of the E230Q mutant of cAMP-dependent protein kinase reveals an unexpected apoenzyme conformation and an extended N-terminal A helix. Protein Sci 14: 28712879.
  • 22
    Zhang J, Yang PL, Gray NS ( 2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9: 2839.
  • 23
    Tripos, L.P ( 2008) Benchware 3D Explorer 2.5. Saint Louis: Tripos L.P.
  • 24
    Nilakantan R, Bauman N, Haraki KS ( 1997) Database diversity assessment: new ideas, concepts, and tools. J Comput-Aided Mol Des 11: 447452.
  • 25
    GVK. GVK Bio Databases. Available at: http://www.gvkbio.com/informatics.html August 2009.
  • 26
    Wissner A, Mansour TS ( 2008) The development of HKI-272 and related compounds for the treatment of cancer. Arch Pharm 341: 465477.
  • 27
    Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC, Grothaus PG, Jeffery DA, Spoerke JM, Honigberg LA, Young PR, Dalrymple SA, Palmer JT ( 2007) Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. Chem MedChem 2: 5861.
  • 28
    Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT ( 2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49: 61776196.
  • 29
    Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, Murray LW, Arendall WBIII, Snoeyink J, Richardson JS, et al. ( 2007) MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 35: W375W383.
  • 30
    Kannan N, Neuwald AF ( 2005) Did protein kinase regulatory mechanisms evolve through elaboration of a simple structural component? J Mol Biol 351: 956972.
  • 31
    Eddy SR ( 1998) Profile hidden Markov models. Bioinformatics 14: 755763.
  • 32
    Sheinerman FB, Giraud E, Laoui A ( 2005) High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding. J Mol Biol 352: 11341156.
  • 33
    Schrodinger (2007) Maestro 8.0. Manual. New York, NY: Schrodinger, p 294.
  • 34
    OpenEye Scientific Software( 2008) OEChemTK 1.6.0. Santa Fe, NM: OpenEye Scientific Software, Inc.